Merck Seeks European License For Cladribine for relapsing remitting MS
Links shared publicly online about this topic.
- 1,867total visits
Merck Seeks European License For Cladribine for relapsing remitting MS
Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes aft
View full resource at medicalnewstoday.com
Tags: Clinical Trial, Merck & Co.
Most Recently Shared on July 27, 2009 at 11:32 am By:
MedNewsToday: Merck Seeks European License For Cladribine for relapsing remitting MS: Merck Serono .. http://bit.ly/NUQkf
Advertisement
